Background
==========

Ceramide is an intracellular lipid second messenger generated in response to a large number of extracellular signals \[[@B1],[@B2]\]. These include tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), ionizing and ultraviolet radiation, anti-cancer drugs, growth-factor withdrawal, infection by human immunodeficiency virus (HIV) or bacteria. It is reported to participate in cell differentiation \[[@B3]\], senescence \[[@B4]\], growth arrest or programmed cell death \[[@B1],[@B2]\], depending on the cell type.

The role of ceramide in programmed cell death or apoptosis has been described in lymphocytes \[[@B5]\], macrophages \[[@B6]\], neurons in primary culture \[[@B7],[@B8]\] and neuronally differentiated PC12 cells \[[@B9],[@B10],[@B11]\]. A number of downstream targets of ceramide have been identified. The best documented are the ceramide-activated protein phosphatases (CAPP) and the ceramide-activated protein kinase (CAPK). The former, represented by the PP1 and PP2A families, mediate the effect of ceramide on the transcription factors c-Myc \[[@B12]\] and c-Jun \[[@B13]\]. CAPK is involved in the mitogen-activated protein (MAP) kinase (MAPK) cascades that include the extracellular-signal regulated kinases (ERK), the c-Jun N-terminal kinases or stress-activated kinases (JNK/ SNK/SAPK) and the p38 family \[[@B14]\].

Recently, it has been shown that C~2~-ceramide rapidly decreases phosphorylation of ERKs, but increases p38 and JNK phosphorylation, activating the transcription factors c-Fos, c-Jun and p53, during the effector phase of apoptosis in primary cortical neurons \[[@B15]\]. It also regulates the protein kinase B (Akt/PKB)-dependent survival pathways, inactivating Akt by dephosphorylation and activating the Bcl-2-related protein BAD by phosphorylation \[[@B16],[@B17],[@B18]\]. Ceramide-induced apoptosis in neurons or in neuronally differentiated PC12 cells has been associated with mitochondrially produced reactive oxygen species (ROS) as well as activation and nuclear translocation of the transcription factor NFκB \[[@B10],[@B11],[@B19]\]. All these molecular events are observed during the effector phase of ceramide-induced apoptosis which also includes gene expression and new protein synthesis required for ceramide-mediated cell death, as it has been shown that neuronal cell death can be inhibited by cycloheximide \[[@B7]\].

The genes that are transcriptionally regulated during ceramide-mediated cell death are still poorly documented. To study gene expression during neuronal cell death, we carried out a differential screen of an array of 9,120 cDNA clones from a human infant brain library (library 1NIB \[[@B20]\]) with complex cDNA targets derived from neuronally differentiated rat pheocytochroma PC12 cells treated with C~2~-ceramide compared to control PC12 cells. This model is particularly suitable for establishing a gene-expression profile during ceramide-mediated neuronal death because first, the neuronal cell population is synchronized and homogeneous, unlike brain tissue or primary neuronal cultures, and second, because the use of exogenous C~2~-ceramide eliminates the risk of interference by transcripts activated by signal transducers upstream of ceramide in the cell-death pathway or in pathways activated in parallel.

Results
=======

Cell death induced in neuronally differentiated PC12 cells by C~2~-ceramide
---------------------------------------------------------------------------

The morphological characteristics of differentiated PC12 cells after 24 hours in the presence of 25 μM C~2~-ceramide were compatible with cell death by apoptosis. Compared with control cultures, as viewed by phase-contrast microscopy (Figure [1a](#F1){ref-type="fig"}), C~2~-ceramide-treated cells lost their neurites and became rounded and shrunken after 24 hours of treatment (Figure [1b](#F1){ref-type="fig"}). The cells that remained viable in the C~2~-ceramide-treated cultures were refringent (Figure [1b](#F1){ref-type="fig"}), like those in the control cultures (Figure [1a](#F1){ref-type="fig"}), and excluded the vital marker propidium iodide (Figure [1c](#F1){ref-type="fig"}), whereas the dead cells took up propidium iodide that intercalated into their DNA (Figure [1d](#F1){ref-type="fig"}), revealing condensed and fragmented nuclei. As previously described, when neuronally differentiated PC12 cells or primary cultures of mesencephalic neurons were treated with cell-permeant C~2~-ceramide (10-50 μM), they died in a dose-dependent manner \[[@B7],[@B10]\]. At 25 μM no significant cell death was observed until 12 hours after the initiation of treatment (Figure [2a](#F2){ref-type="fig"}). After 24 hours, 50% of the cells had died. By 48 hours, no viable cells remained. Furthermore, we observed activation of caspase-3/CPP32, a member of the cysteine-activated aspartate family of cell-death proteases \[[@B21]\], that started 8 hours after the beginning of ceramide treatment and was five times the control value by 18 hours (Figure [2b](#F2){ref-type="fig"}). No significant cell death and caspase-3/CPP32 activity were observed using the inactive C2 analog of ceramide, C~2~-dihydroceramide (Figure [2](#F2){ref-type="fig"}).

Validation of hybridization signals
-----------------------------------

Hybridization of 9,120 cDNA clones with complex cDNA targets from poly(A)^+^ RNA extracted from C~2~-ceramide-treated or control cells produced signals of varying intensities (Figure [3a](#F3){ref-type="fig"}). In order to eliminate clones for which no reproducible hybridization signals were obtained, the signal-intensity values were validated as described in Materials and methods. Thus, 7% of the clones hybridized with the control cDNA target (634) and 14% of clones hybridized with the C~2~-ceramide-treated cDNA target (1,297) were excluded from further analysis. The remaining 6,494 clones were analyzed for differential hybridization.

Differential gene expression in neuronally differentiated PC12 cells treated with C~2~-ceramide compared to controls
--------------------------------------------------------------------------------------------------------------------

Changes in gene expression were analyzed during the effector phase of neuronal death, 7 hours after the beginning of C~2~-ceramide treatment. This time point was chosen because on the one hand it is preceded by the activation of the transcription factor NFκB and c-Jun observed 4 to 6 hours after C~2~-ceramide treatment in PC12 cells \[[@B10],[@B22]\], and on the other, the apoptotic process is still not induced by caspase-3 activation, which occurs 8 hours after the beginning of C~2~-ceramide treatment.

Hybridization between the rat PC12 cell-derived targets and the human cDNA macroarray was carried out as described in Materials and methods. Modulation of gene expression was quantitated by calculating the ratio of the intensity of the normalized hybridization signal obtained with the C~2~-ceramide cDNA target to that obtained with the control target. Clones were considered to be differentially hybridized in C~2~-ceramide-treated cells compared to control cells if the ratio between the corresponding hybridization intensity values was ≥ 2 (up-hybridized clones) or ≤ 0.5 (down-hybridized clones) which are the limits of confidence for the method. To decrease the risk of false-positive results, clones with hybridization signals that were less than twofold above background were also excluded, resulting in the elimination of 538 clones. In addition, the remaining clones were hybridized with complex cDNA targets from poly(A)^+^ RNA extracted from C~2~-dihydroceramide-treated cells used as negative control and compared to untreated cells. No modulation of expression was observed (except for one clone excluded from the analysis) in the presence of this inactive analog of C~2~-ceramide (data not shown). Among the 239 clones that met the criteria for differential hybridization, 132 were up-hybridized in C~2~-ceramide-treated cells and 107 were down-hybridized. The distribution of the hybridization-intensity values between the control and the C~2~-ceramide complex cDNA targets is presented in Figure [3b](#F3){ref-type="fig"}. Approximately 55% (72/132) of the up-hybridized clones were hybridized 3-6-fold more in C~2~-ceramide-treated cells than in the control and 40% (41/107) of the down-hybridized clones were hybridized 3-9-fold less.

Partial 5\' and 3\' sequences of the 239 clones were compared with all the sequences in the database developed in our laboratory (the Genexpress Index \[[@B23]\]) and in public databases. Of the 239 clones, 179 clones corresponded to already identified human genes, 113 of which have defined functions. The remaining 60 clones corresponded to genes with limited characterization. Under the hypothesis that differential hybridization of the clones reflects linear modulation of expression of the corresponding genes, we assume that we have detected differential gene expression using cDNA array technology that can be interpreted according to the information available.

Ten differentially expressed genes encode proteins with a role in ceramide or TNF-α signaling pathways (Figure [4](#F4){ref-type="fig"}, Table [1](#T1){ref-type="table"}; see \[[@B24]\] for links to database entries for each gene). Two of these genes, *PLA2G4C* \[[@B25]\] and *CLN3* \[[@B26],[@B27]\] seem to have a role in ceramide-mediated cell death or survival. Two upregulated genes (*ETV5* \[[@B28]\], *NPTX2* \[[@B29],[@B30]\]) and two downregulated genes (*COL1SA1* \[[@B31],[@B32]\], *TNFAIP1* \[[@B33]\]) encode proteins that are modulated by TNF-α. Four genes, three upregulated (*AXL* \[[@B34]\], *BIRC1* \[[@B35]\], *RSU1* \[[@B36]\]) and one downregulated (*MAPK10* \[[@B37]\]) encode proteins with a role in the TNF-α signaling pathway.

Twenty clones correspond to genes encoding proteins that have been involved in the regulation of apoptosis and/or cell growth (Figure [5](#F5){ref-type="fig"}, Table [2](#T2){ref-type="table"}, see \[[@B24]\]). Fourteen are up-hybridized and six are down-hybridized by C~2~-ceramide. Ten of the upregulated and two of the downregulated genes encode proteins stimulating apoptosis and/or growth arrest. The other genes (four upregulated and four downregulated) encode proteins downregulating apoptosis and/or stimulating growth.

The remaining 83 clones corresponding to 82 genes with known or putative functions have no obvious relation to the apoptosis process (Table [3](#T3){ref-type="table"}, see \[[@B24]\]). Of the total number of differentially hybridized clones, 66 correspond to mRNA sequences (Table [4](#T4){ref-type="table"}, see \[[@B24]\]) and 60 to poorly characterized genes (Table [5](#T5){ref-type="table"}, see \[[@B24]\]) that encode proteins without known function.

To confirm the results obtained by macroarray analysis, differentially expressed transcripts representing upregulated or downregulated genes were analyzed for differential expression by reverse transcription PCR (RT-PCR) or northern blots. As shown in Figure [6](#F6){ref-type="fig"}, the upregulation of *ETV5, M6PR* and APCL was confirmed by RT-PCR, and the downregulation of two genes with unknown function (mRNA DKFZp586C1723 and *GENX 2969*) was confirmed by northern blotting.

Discussion
==========

Extracellular signaling molecules such as cytokines, growth-factor deprivation and DNA damage caused by chemotherapeutic agents or irradiation activate ceramide-mediated signal transduction pathways leading to cell death. These pathways have been investigated in the immune system, where they are known to have an important role, and in neurons, as they are suspected to play a part in neurodegenerative disorders \[[@B1]\]. A number of steps in the signaling cascades have been elucidated. However, although the translation inhibitor cycloheximide inhibits the ceramide-mediated death of mesencephalic neurons \[[@B7]\], the expression patterns of genes modulated during ceramide-mediated cell death remain unknown. In a global approach to this question, we have used cDNA macroarray technology to determine the profile of gene expression in a neuronal model of cell death, neuronally differentiated and C~2~-ceramide-treated PC12 cells, in which ceramide-dependent changes in gene expression could be isolated from the effects of other transcription modulators.

Identification of genes closely implicated in the ceramide and/or TNF-α signaling pathway
-----------------------------------------------------------------------------------------

We were able to detect differential expression of 10 genes known to be involved in the ceramide or TNF-α signaling pathways (see Figure [4](#F4){ref-type="fig"}, Table [1](#T1){ref-type="table"}) thus validating our study. A summary illustration of the putative role of these genes is presented in Figure [7](#F7){ref-type="fig"}. Briefly, two genes, encoding phospholipase A2 group IVC (*PLA2G4C*) and ceroid-lipofuscinosis, neuronal 3, juvenile (*CLN3*) are already known to be involved in ceramide-mediated signal transduction. The first, *PLA2G4C,* belongs to the cytosolic phospholipase A2 gene family that encodes two different proteins: calcium-independent and calcium-dependent cytosolic phospholipases \[[@B38]\]. TNF-α regulates the expression of *PLA2G4A* mRNA in HeLa cells \[[@B39]\] and in human bronchial epithelial cells \[[@B40]\], which is indirect evidence of modulation by ceramide, but the role of ceramide was not demonstrated directly in these studies. However, ceramide was shown directly to upregulate the expression of the gene encoding cytosolic phospholipase A2 in the fibroblast cell line L929 \[[@B41]\]. Conversely, the activation of this gene was reported to be necessary for ceramide accumulation and cell death in the same cells \[[@B25]\]. We show for the first time that this gene is involved in neuronal apoptosis.

The second gene, *CLN3,* is expressed in a variety of human tissues including the brain, where the product is necessary for neuronal survival \[[@B26],[@B27]\]. Interestingly, *CLN3* does not inhibit C~2~-ceramide-induced apoptosis but modulates endogenous ceramide synthesis and suppresses apoptosis by preventing generation of ceramide \[[@B42]\]. Thus, C~2~-ceramide can activate a negative feedback mechanism regulating endogenous ceramide generation as well as activate the downstream targets of the endogenous lipid.

Four other genes or families of genes known to be transcriptionally regulated by TNF-α were also modulated by C~2~-ceramide in our model (Table [1](#T1){ref-type="table"}). Of these, *ETS variant 5 (ETV5)* belongs to the family of ETS transcription factor genes. Increased expression of both *ETS1* mRNA and the protein has been observed in human fibroblasts after TNF-α or IL-1β stimulation \[[@B28]\]. PEA3 (a mouse protein corresponding to ETV5) inhibits tumorigenesis *in vivo* \[[@B43]\]. Moreover, ETV5 and ETS1 can cooperate with c-Jun/c-Fos \[[@B44],[@B45]\], potential regulators of apoptosis in many cell types and specially in the mammalian nervous system \[[@B46]\]. The second gene regulated by TNF-α is *NPTX2,* encoding neuronal pentraxin II. Pentraxins are a family of proteins that include C-reactive protein and serum amyloid P. They have been found in the brain plaques characteristic of Alzheimer\'s disease and are toxic to neuronal cell cultures \[[@B47],[@B48]\]. Furthermore, the expression of *NPTX3* is increased in response to TNF-α or IL-1β stimulation via activation of NFκB \[[@B29],[@B30]\]. The regulation of the pentraxin gene family by C~2~-ceramide treatment is consistent with our previous studies showing NFκB activation by C~2~-ceramide in PC12 cells and in primary cultures of neurons \[[@B10],[@B19]\]. The last two genes known to be regulated by TNF-α and identified in our model are *COL18A1,* encoding type XVIII collagen alpha 1, and *TNFAIP1,* encoding TNF-α-induced protein 1. These proteins, downregulated by C~2~-ceramide, are modulated by TNF-α in various cell types \[[@B31],[@B32],[@B33]\].

We also identified four genes encoding proteins known to participate in TNF-α-activated signal transduction pathways. Thus *AXL,* upregulated by a factor of 3.65 (Table [1](#T1){ref-type="table"}), encodes a tyrosine kinase receptor. Signaling through this receptor is reported to protect against TNF-α-induced apoptosis in fibroblasts and its absence increases apoptosis after serum deprivation \[[@B34]\]. Interestingly, ARK, the mouse protein corresponding to AXL, activates the survival pathway mediated by the serine-threonine kinase Akt \[[@B49]\], which is negatively regulated by ceramide \[[@B16],[@B17],[@B50]\], and is also reported to modulate ceramide synthesis \[[@B51]\]. The second gene we identified is *BIRC1,* encoding baculoviral IAP repeat-containing 1 protein. This protein, putatively involved in spinal muscular atrophy \[[@B52]\], is an inhibitor of cell death induced by various apoptotic stimuli, including TNF-α \[[@B35]\]. The third identified gene, *RSU1,* encodes Ras suppressor protein 1, which is involved in TNF-α signaling by blocking the Ras-dependent response. Levels of both *RSU1* mRNA and protein have been correlated with a decrease in growth rate and tumorigenic potential in U251 glioblastoma cells \[[@B53]\] and it induces growth arrest in PC12 cells \[[@B36]\]. This is consistent with the report that ceramide regulates apoptosis via modulation of the Ras signaling pathway \[[@B18]\]. In addition, RSU1 has been identified as an inhibitor of Jun kinase activation \[[@B37]\]. This point is interesting, as the fourth gene presenting in this group, *MAPK10/J.NK3,* encoding the JNK family member mitogen-activated protein kinase 10, is downregulated by C~2~-ceramide in our model.

The identification of these eight genes, which are involved in the TNF-α signaling pathway, in C~2~-ceramide treated PC12 cells, suggests that their modulation of expression by TNF-α could be the result of a ceramide-dependent mechanism.

Commitment to apoptosis: upregulation of pro-apoptotic genes and downregulation of anti-apoptotic genes by the ceramide pathway
-------------------------------------------------------------------------------------------------------------------------------

Twenty genes regulated by C~2~-ceramide correspond to genes known to be involved in regulation of apoptosis and/or cell growth (Figure [5](#F5){ref-type="fig"}, Table [2](#T2){ref-type="table"}). Twelve of these genes are known to be associated with oncogenesis and four with neuronal disorders. Of the upregulated genes, 10 out of 14 are known to be associated with a pro-apoptotic or anti-proliferation process and 3 out of 14 are mainly implicated in protection of the cell against cytotoxicity or damage. Of the downregulated genes, 4 out of 6 are associated with an anti-apoptotic or a proliferation process. This highlights the fact that the cells are engaged in programmed cell death. The putative roles of these genes are illustrated in Figure [7](#F7){ref-type="fig"}, which focuses on the pro-apoptotic or anti-proliferation process versus anti-apoptotic or proliferation processes.

Briefly, of the known pro-apoptotic or anti-proliferative genes that are upregulated in our model, *RPL4* encodes the ribosomal protein L4 that has been shown to be transcriptionally stimulated prior to apoptosis induced by the 5-azacytidine in the PC12 cells \[[@B54]\]. *PDCD6IP,* upregulated by C~2~-ceramide in our model, encodes a protein that interacts with ALG2, a Ca^2+^-binding protein that is required for apoptosis induced by diverse stimuli, including ceramide treatment \[[@B55],[@B56],[@B57]\]. *M6PR* encodes the cation-dependent mannose-6-phosphate receptor, which has been implicated in retinoid-induced apoptosis \[[@B58]\]. *NMA,* encoding a putative transmembrane protein, is expressed at low levels in metastatic human melanoma cell lines and xenografts, and is completely absent in highly metastatic human melanoma cell lines \[[@B59]\]. *APCL,* encoding adenomatous polyposis coli like protein, is a tumor-suppressor gene \[[@B60]\]. *METAP2* encodes methionine aminopeptidase eIF-2-associated p67, which interacts with eukaryotic translation initiation factor eIF-2 \[[@B61]\] and could regulate p53 signaling \[[@B62]\]. *BAT3,* downregulated in some transformed cells, encodes HLA-B associated transcript-3, which interacts with the tumor-suppressor protein DAN that contains growth or tumor suppressive activity *in vitro* \[[@B63]\]. *PHB* encodes the protein prohibitin, a potential tumor-suppressor protein that binds to the retinoblastoma (Rb) protein and represses E2F transcriptional activity \[[@B64],[@B65]\]. *BNIP3L,* encoding BCL2/adenovirus E1B 19 kD-interacting protein 3-like, is a pro-apoptotic gene which has a growth-inhibitory effect on cancer cells \[[@B66]\]. *CDH13,* encoding cadherin 13, is significantly downregulated in human breast carcinoma cell lines and breast cancer, whereas its overexpression decreases tumor-cell growth \[[@B67],[@B68]\].

Of the known anti-apoptotic or proliferative genes that are downregulated in our model, *LOC51582* encodes an antizyme inhibitor, which regulates the antizyme activity proposed to be involved in the polyamine biosynthesis pathway \[[@B69],[@B70]\]. Interestingly, overexpression of antizyme inhibits cell growth \[[@B71],[@B72]\], whereas *LOC51582* is downregulated in our model. This observation is consistent with a role of antizyme in the apoptotic process and suggests that ceramide can regulate its activity. *LOC51283,* a regulator of the activity of the Bcl-2 family proteins, encodes a novel apoptosis regulator, which has been identified as an inhibitor of Bax-induced cell death \[[@B73]\]. Its downregulation by C~2~-ceramide confirms its involvement in the ceramide-dependent regulation of cell death. The last gene presented here, *MET,* encodes the MET proto-oncogene, known to be a receptor of the hepatocyte growth factor that has been described to protect neuronal cells from apoptosis via the phosphatidylinositol-3 kinase/Akt pathway \[[@B74]\].

Four genes out of the other genes presented in Table [2](#T2){ref-type="table"} have already been implicated in neuronal disorders, suggesting that ceramide may be a key second messenger in these pathologies. The upregulation of the glutamate receptor gene (*GRIA2*) seems to be an indicator of tolerance to ischemia \[[@B75]\]. The absence of somatostatin, encoded by *SST* (downregulated in our model), is associated with apoptotic neurons in patients with Alzheimer\'s disease \[[@B76]\]. *SMN,* encoding Survival of motor neuron 2, downregulated by C~2~-ceramide, strongly contributes to the severity of the spinal muscular atrophy \[[@B77]\]. *MUT mRNA* is upregulated in ischemia, in relation to a decrease in the accumulation of its neurotoxic metabolite \[[@B78]\].

In conclusion, our cell culture model has enabled us to establish a profile of gene expression during the effector phase of ceramide-mediated cell death. In spite of the stringency of the criteria adopted for differential hybridization, a large number of cDNA clones, 239 of the 9,120 in our cDNA array derived from a normalized infant brain library, correspond to genes up- or downregulated by C~2~-ceramide treatment. Already-known genes account for 179 of the transcripts, 113 of which have a putative function.

On the basis of their putative functions, we have made an attempt at classifying these transcripts, first with respect to known effects of ceramide or ceramide-mediated transduction systems, then with respect to regulation of cell growth and apoptosis. The 30 genes in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} met these criteria, validating the approach and suggesting that the other modulated genes may also be relevant with regard to the progression of the cell-death mechanisms. These genes were classified as having no obvious relation to cell death or survival (Table [3](#T3){ref-type="table"}), no known function (Table [4](#T4){ref-type="table"}) or as poorly characterized (Table [5](#T5){ref-type="table"}). As a result of our study, these genes now have tentative functions. The full list can be consulted with the relevant data on the dedicated website \[[@B24]\].

Interestingly, given the large number of genes known to be modulated by NFκB in the immune system \[[@B79]\], it was surprising that only pentraxin was detected in our model. This suggests either that NFκB is less important in neurons than in lymphocytes, or that its targets are different. Conversely, the transcriptional regulators responsible for the differential expression of the genes detected in our study remain to be discovered. In any case, our results show that transcriptional regulation plays an important role in ceramide-mediated cell death and that some of the modulated transcripts, in agreement with published studies, are involved in other cell-death mechanisms as well.

Materials and methods
=====================

Cell culture
------------

Rat PC12 cells \[[@B80]\], which acquire a neuronal phenotype in the presence of nerve growth factor (NGF), were plated at a density of 2,000-3,000 cells/cm^2^ in 75 cm^2^ culture flasks coated with polyethylenimine (1 mg/ml) in Leibovitz modified L15 medium (Gibco BRL) supplemented with 2% horse serum and 150 ng/ml NGF (grade II; Alomone Labs, Jerusalem, Israel) as previously described \[[@B81]\]. Apoptosis was induced, after 6 days in the presence of NGF, with the cell-permeant C~2~ analog of ceramide (C~2~-ceramide), N-acetylsphingosine (Biomol Research Laboratories, Plymouth Meeting, PA), at a concentration of 25 μM. As negative control, an inactive C~2~ analog of ceramide (C~2~-dihydroceramide), N-acetylsphinganine (Biomol Research Laboratories), was used in the same condition as C~2~-ceramide.

Morphological characterization of apoptosis and cell counts
-----------------------------------------------------------

Neurite retraction and cell shrinkage were visualized by phase-contrast microscopy. Condensed and fragmented nuclei were made visible *in situ* as described in \[[@B7]\], by intercalation into nuclear DNA of the fluorescent probe propidium iodide. Propidium iodide, which only enters dead cells that have become permeable, was visualized by epifluorescence with a rhodamine filter (excitation, 548-580 nm; emission, 580-610 nm). Viability was quantified by counting cells in at least 10 randomly chosen fields with a 20x objective. The percentage of cells excluding the vital dye propidium iodide was calculated at each time point after the beginning of C~2~-ceramide or C~2~-dihydroceramide treatment with respect to the corresponding control.

Measurement of caspase-3-like activity
--------------------------------------

Caspase-3-like activity was measured using the CaspACE Assay system (Promega, Madison, WI). Cell extracts containing equivalent amounts of protein were used to measure DEVDase (caspase-3-like) activity: the chromophore p-nitroaniline (pNA), released from the colorimetric substrate (Ac-DEVD-pNA) upon cleavage by DEVDase produces a yellow color that is monitored by a photometer at 405 nm.

Preparation of the cDNA macroarray
----------------------------------

cDNA clones from a normalized infant brain library (library 1NIB; \[[@B20]\]) were randomly selected to provide a set of 9,120 cDNA clones. The 3\' and/or 5\' ends of these clones had been previously sequenced \[[@B25]\]. The sequences, registered in GenBank \[[@B82]\], were compared to those in public data bases, permitting tentative identification of the corresponding gene transcripts. The cDNA clones were used to prepare PCR products using oligonucleotide primers complementary to sequences in the vector. They were spotted by robot (Flexis; Perkin Elmer, Shelton, CT) at medium density (25 PCR products/cm^2^) on nylon membranes (Hybond-N+; Amersham Biosciences, Uppsala, Sweden) as previously described \[[@B83]\]. The entire collection of 9,120 cDNA clones was spotted on a set of four filters.

Purification of poly(A)^+^ mRNA
-------------------------------

Total RNA was extracted from control PC12 cultures and from PC12 cultures treated with C~2~-ceramide or C~2~-dihydroceramide (approximately 10^6^ cells) with the RNeasy midi kit (Qiagen, Courtaboeuf, France), according to the manufacturer\'s instructions. The integrity of the RNA was confirmed by agarose gel electrophoresis. Poly(A)^+^ mRNA was extracted from total RNA with oligo(dT)-conjugated magnetic beads (Dynabeads; Dynal, Oslo, Norway), as described in the manufacturer\'s protocols.

Complex cDNA target synthesis
-----------------------------

Complex cDNA targets were synthesised by reverse transcription of 500 ng poly(A)^+^ mRNA extracted from control, C~2~-dihydroceramide- or C~2~-ceramide-treated PC12 cells. The reaction was performed with the Superscript™ Preamplification System (Invitrogen) as previously described \[[@B84]\]. The reaction mixture contained random-oligonucleotide primers (500 ng), 50 μCi \[α-^33^P\]dATP, 3,000 Ci/mmol (Amersham), 500 μM d(T, C, G)TP (Amersham) and 50 μM dideoxyGTP (Invitrogen).

Filter hybridization
--------------------

The filters were prehybridized at 68°C for 30 min in ExpressHyb hybridization solution (Clontech, Palo Alto, CA), hybridized for 2 h in the same solution to which the radiolabeled complex cDNA target was added, then washed twice for 30 min at 25°C in standard saline citrate (SSC) 1×/0.1% sodium dodecyl sulfate (SDS) and twice for 30 min at 25°C in SSC 0.1×/0.1% SDS. The washed filters were exposed to phosphorus screens (Molecular Dynamics, Sunnyvlae, CA) for 16 h.

Hybridization signal quantitation
---------------------------------

Image acquisition was carried out with the Phosphorlmager (Molecular Dynamics). The hybridization signal corresponding to each cDNA clone was quantitated with a specifically designed software (XdotsReader; Cose, Dugny, France) and the local background signal was subtracted. The intensity of the hybridization signal for each clone was then divided by the average intensity of all the clones on each filter to obtain normalized values. Hybridization was done in quadruplicate so that, for each clone/target combination, four values were obtained, compared and validated if at least three out of the four values were similar (SD ± 25%). The final value assigned to each clone was the average of the validated values.

Northern blotting
-----------------

Total RNA (20 μg) were fractionated under denaturing conditions in a 1.2% agarose gel and transferred onto a Hybond-N+ membrane (Amersham). Specific probes were generated from cDNA clones of interest by PCR using vector-specific primers. The PCR products were purified using the microcon kit (Amicon, Wageningen, The Netherlands) and radiolabeled by random priming (Gibco BRL). Oligonucleotides corresponding to 18S rRNA (control probe) were ^32^P-labeled using \[γ-^33^P\]ATP and T4 RNA kinase. For northern blot analysis, the blots were prehybridized 2 h in ULTRAhyb hybridization buffer (Ambion, Austin, TX), hybridized with the labelled probe (1-2 × 10^6^ cpm/ml) for 16 h at 42°C in the same solution, and washed as for the high-density filters. The washed filters were exposed to phosphorus screens (Molecular Dynamics) for 48 h. The hybridization signal of the specific probes was analyzed with the ImageQuant software (Molecular Dynamics) and compared to the signal obtained with the control probe.

RT-PCR
------

Total RNA of PC12 cells cultured with or without C~2~-ceramide was purified according to the protocol described above. Total RNA (2 μg) were reverse transcribed using the Superscript™ Preamplification System (Invitrogen) according to the manufacturer\'s protocol. An aliquot of the reaction was then used for PCR amplification with the Advantage PCR kit (Clontech) and primers specific to the gene of interest. The amplification products were visualized after electrophoresis in a 1.5% agarose gel with ethidium bromide. The signals were analyzed with ImageQuant software and compared to *HPRT* (hypoxanthine phosphoribosyl transferase) as control gene.
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![Morphological characteristics of nerve growth factor (NGF)-differentiated PC12 cells during C~2~-ceramide-induced apoptosis. **(a)** Control cultures of PC12 cells after 6 days in the presence of NGF viewed by phase-contrast microscopy; **(b)** NGF-differentiated PC12 cells after 24 h treatment with 25 μM C~2~-ceramide. Open arrows, viable cells; white arrows, dead cells. **(c,d)** Condensed and fragmented nuclei of dead cells in (c) control and (d) NGF-differentiated PC12 cells visualized by intercalation of propidium iodide into DNA were viewed under epifluorescence illumination.](gb-2002-3-8-research0042-1){#F1}

![Characterization of C~2~-ceramide-induced apoptosis. **(a)** Time course of cell death induced by 25 μM C~2~-ceramide (circles) or by 25 μM C~2~-dihydro-ceramide (triangles). Cells were counted in at least 10 randomly chosen fields with a 20x objective. The percentage of cells excluding the vital dye propidium iodide was calculated at each time point after the beginning of C~2~-ceramide treatment with respect to the corresponding control. **(b)** Time course of caspase-3-like activity after 25 μM C~2~-ceramide (circles) or 25 μM C~2~-dihydroceramide (triangles) treatment. Data are mean ± SEM (bars) values of at least three experiments, performed in triplicate. The black arrows indicate the time of C~2~-ceramide treatment of the cell cultures used in the expression study.](gb-2002-3-8-research0042-2){#F2}

![Hybridization signal analysis. **(a)** Macroarray of 9,120 cDNA clones hybridized with complex cDNA targets derived from mRNA of neuronally differentiated PC12 cells without C~2~-ceramide treatment (control) or treated with C~2~-ceramide (stimulated). **(b)** Distribution of the hybridization signal intensities between control and stimulated cells. Some genes identified in the present study are indicated.](gb-2002-3-8-research0042-3){#F3}

![Differentially expressed genes that encode proteins with functions involved in ceramide-dependent apoptosis. Black boxes, Genes involved in the ceramide signaling pathway; gray boxes, genes transcriptionally stimulated by TNF-α; white boxes, genes involved in the TNF-α signaling pathway.](gb-2002-3-8-research0042-4){#F4}

![Differentially expressed genes that encode proteins involved in the regulation of apoptosis and/or cell growth. Gray boxes, genes stimulating apoptosis and/or growth arrest; white boxes, genes downregulating apoptosis and/or stimulating growth.](gb-2002-3-8-research0042-5){#F5}

![Confirmation of macroarray results by RT-PCR and northern blotting. The percentage of signal modulation (PCR amplification signal or hybridization signal) in relation to control cells (without C~2~-ceramide treatment) has been calculated in each condition to compare the expression of each gene in neuronally differentiated PC12 cells with (black boxes) or without (white boxes) C~2~-ceramide treatment. The PCR amplification signal and the hybridization signal for the positive controls (*HPRT* and 18S rRNA genes, respectively) are indicated.](gb-2002-3-8-research0042-6){#F6}

![Schematic illustrating the putative roles of the proteins encoded by the genes noted in Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}.](gb-2002-3-8-research0042-7){#F7}

###### 

Genes differentially expressed in ceramide-dependent apoptosis and involved in the ceramide and TNF-α pathways

  Clone ID                                                GENX     GenBank accession number   Unigene     C. int.   C. SD   S. int.   S. SD   Ratio   Similarity                                                                      Gene symbol
  ------------------------------------------------------- -------- -------------------------- ----------- --------- ------- --------- ------- ------- ------------------------------------------------------------------------------- -------------
  Genes involved in the C~2~-ceramide signaling pathway                                                                                                                                                                               
   yf59e08                                                5705     R13531                     Hs.18858    3.56      0.54    12.01     0.86    3.37    Phospholipase A2, group IVC (cytosolic, calcium-independent)                    *PLA2G4C*
   yf71a08                                                115123   R12998; R40387             Hs.194660   1.14      0.23    2.53      0.15    2.21    Ceroid-lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeyer-Vogt disease)   *CLN3*
  Genes transcriptionally stimulated by TNF-α                                                                                                                                                                                         
   yg86b08                                                4272     R53048; R53135             Hs.43697    1.72      0.18    8.77      0.58    5.09    Ets variant gene 5 (ets-related molecule)                                       *ETV5*
   yc86d06                                                5838     F12910; T75064             Hs.3281     3.61      0.48    11.54     0.61    3.19    Neuronal pentraxin II                                                           *NPTX2*
   yc88f11                                                197      F10424; F12821             Hs.78409    1.18      0.21    0.55      0.11    0.47    Collagen, type XVIII, alpha 1                                                   *COL18A1*
   yf78g01                                                200888   R14176; R40470             Hs.76090    1.19      0.28    0.54      0.06    0.46    TNF-α-induced protein 1 (endothelial)                                           *TNFAIP1*
  Genes involved in the TNF-α signaling pathway                                                                                                                                                                                       
   yf76d09                                                1017     R13424; R40936             Hs.83341    1.49      0.23    5.45      0.54    3.65    AXL receptor tyrosine kinase                                                    *AXL*
   yg49f10                                                116415   R20716                     Hs.79019    4.54      0.13    12.69     1.38    2.80    Baculoviral IAP repeat-containing 1                                             *BIRC1*
   c-26g10                                                1350     F07467                     Hs.75551    1.37      0.27    2.81      0.56    2.05    Ras suppressor protein 1                                                        *RSU1*
   c-08d10                                                4997     F05370; Z38358             Hs.151051   4.94      1.06    2.41      0.51    0.49    Mitogen-activated protein kinase 10                                             *MAPK10*

Clone ID, clone name according to the public databases. GENX, cluster name including the corresponding cDNA sequence in the Genexpress Index 2 (\[[@B23]\] and R. Mariage-Samson *et al.,* unpublished data). UniGene, cluster name in the UniGene database \[[@B85]\]; C. int., mean of the normalized and validated intensity values obtained after filter hybridization with complex cDNA target derived from control mRNA. C. SD, standard deviation derived from the C.int. S. int., mean of the normalized and validated intensity values obtained after filter hybridization with complex cDNA target derived from ceramide-stimulated cultured cell mRNA. S. SD, standard deviation derived from the S. int. Ratio, ratio of S. int. to C. int. Similarity, gene similarity.

###### 

Differentially expressed genes that encode proteins involved in the regulation of apoptosis and/or cell growth

  Clone ID                                                      GENX     GenBank accession number   Unigene     C. int.   C. SD   S. int.   S. SD   Ratio   Similarity                                               Gene symbol
  ------------------------------------------------------------- -------- -------------------------- ----------- --------- ------- --------- ------- ------- -------------------------------------------------------- -------------
  Proteins stimulating apoptosis and/or growth arrest                                                                                                                                                                
   yg01b10                                                      2112     R18353; R42557             Hs.286      1.68      0.17    7.95      0.55    4.74    Ribosomal protein L4                                     *RPL4*
   yl73h11                                                      567      H06473                     Hs.9663     1.60      0.15    7.42      0.54    4.64    Programmed cell death 6-interacting protein              *PDCD6IP*
   yc92h11                                                      673      F13260; T77039             Hs.75709    2.12      0.33    9.83      0.95    4.64    Mannose-6-phosphate receptor (cation dependent)          *M6PR*
   yg94h08                                                      6030     R56149                     Hs.78776    1.96      0.34    7.09      1.25    3.61    Putative transmembrane protein                           *NMA*
   yf90d04                                                      25970    R15366                     Hs.20912    1.34      0.22    4.71      0.58    3.51    Adenomatous polyposis coli like                          *APCL*
   yg76b02                                                      3804     R51346; R51453             Hs.78935    0.95      0.18    2.89      0.40    3.03    Methionine aminopeptidase; eIF-2-associated p67          *METAP2*
   yd01h06                                                      9451     R39334; T78769             Hs.274348   1.98      0.16    5.89      0.66    2.97    HLA-B associated transcript-3                            *BAT3*
   c-22F12                                                      2915     F08770                     Hs.75323    1.44      0.23    3.26      0.29    2.26    Prohibitin                                               *PHB*
   yf69g07                                                      115124   R14126                     Hs.132955   1.82      0.30    3.99      0.96    2.19    BCL2/adenovirus E1B 19 kD-interacting protein 3-like     *BNIP3L*
   yd02b11                                                      115910   T79985                     Hs.63984    0.88      0.19    1.88      0.30    2.14    Cadherin 13, H-cadherin (heart)                          *CDH13*
   c-3ke04                                                      781      F10823; F13223             Hs.12409    1.17      0.10    ND        ND      0.43    Somatostatin                                             *SST*
   yg64g08                                                      115205   R35542; R51110             Hs.288986   3.01      0.41    0.90      0.15    0.30    Survival of motor neuron 1 1, telomeric                  *SMN1*
  Proteins downregulating apoptosis and/or stimulating growth                                                                                                                                                        
   yg44d03                                                      408      R25503                     Hs.155212   1.74      0.40    7.67      0.40    4.40    Methylmalonyl coenzyme A mutase                          *MUT*
   yg68d10                                                      2957     R36284; R49571             Hs.89582    1.80      0.25    7.26      0.57    4.04    Glutamate receptor, ionotropic, AMPA 2                   *GRIA2*
   yl81d04                                                      9379     H05457; H07007             Hs.150423   2.64      0.36    8.72      1.06    3.31    Cyclin-dependent kinase 9 (CDC2-related kinase)          *CDK9*
   yd02a11                                                      78693    T79973                     Hs.107911   2.52      0.42    5.38      0.44    2.14    ATP-binding cassette, sub-family B (MDR/TAP), member 6   *ABCB6*
   yg51a11                                                      17820    R21694; R46587             Hs.223014   1.09      0.24    ND        ND      0.46    Antizyme inhibitor                                       *OAZIN*
   yh10g09                                                      4858     R61276; R61277             Hs.8073     1.59      0.23    0.66      0.16    0.41    Septin 3                                                 *SEP3*
   yf53a12                                                      3165     R12025; R37093             Hs.356245   1.14      0.21    0.29      0.02    0.25    Apoptosis regulator                                      *LOC51283*
   yg67b12                                                      115951   R35827;                    Hs.285754   2.38      0.48    0.50      0.12    0.21    Met proto-oncogene                                       *MET*

Abbreviations and column headings are as in Table [1](#T1){ref-type="table"}.

###### 

Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process

  Clone ID                                 GENX     GenBank accession number   Unigene     C. int.   C. SD   S. int.   S. SD   Ratio   Similarity                                                                                                Gene symbol
  ---------------------------------------- -------- -------------------------- ----------- --------- ------- --------- ------- ------- --------------------------------------------------------------------------------------------------------- --------------------
  Signal transduction                                                                                                                                                                                                                            
   yl85b10                                 1842     H05211                     Hs.22003    1.62      0.40    7.99      0.37    4.94    Solute carrier family 6 (neurotransmitter transporter, GABA), member 1                                    *SLC6A1*
   yf77g11                                 3900     R14207; R37490             Hs.75819    1.12      0.12    5.02      0.43    4.46    Glycoprotein M6A                                                                                          *GPM6A*
   yg63f10                                 1552     R26636; R49665             Hs.24212    1.01      0.15    4.02      0.61    3.98    Latrophilin                                                                                               *KIAA0786*
   c-2ee07                                 116218   Z45003                     Hs.107979   1.75      0.35    6.17      0.85    3.52    Small membrane protein 1                                                                                  *SMP1*
   yf60h11                                 12653    R13771                     Hs.61628    1.43      0.18    4.68      0.61    3.28    Calcium binding atopy-related autoantigen 1                                                               *CBARA1*
   yf88a09                                 9668     R15201                     Hs.181326   4.01      0.50    11.65     2.01    2.90    Myotubularin-related protein 2                                                                            *MTMR2*
   yg11b08                                 107475   R17181; R41731             Hs.5462     0.72      0.12    1.54      0.33    2.14    Solute carrier family 4, sodium bicarbonate cotransporter, member 4                                       *SLC4A4*
   c-2mh12                                 1997     Z41050; Z45338             Hs.108787   1.08      0.21    0.52      0.04    0.47    Phosphatidylinositol glycan, class N                                                                      *PIGN*
   yc87e10                                 115203   F10343; F12737             Hs.173717   1.24      0.17    0.50      0.06    0.40    Phosphatidic acid phosphatase type 2B                                                                     *PPAP2B*
   yf48c10                                 9043     R12286; R12797             Hs.10842    1.10      0.24    0.43      0.03    0.39    RAN, member RAS oncogene family                                                                           *RAN*
   yd09f12                                 2991     R39085                     Hs.306359   2.39      0.46    0.90      0.22    0.38    Hect domain and RCC1 (CHC1)-like domain (RLD) 1                                                           *HERC1*
   c-3ie05                                 5307     F10685; F13091             Hs.9347     1.48      0.24    0.53      0.02    0.36    Regulator of G-protein signaling 14                                                                       *RGS14*
   yg16c08                                 5294     R17962; R43452             Hs.1440     1.05      0.23    0.29      0.04    0.27    Gamma-aminobutyric acid (GABA) A receptor, beta 3                                                         *GABRB3*
   yf50c04                                 1366     R11777; R37698             Hs.5985     1.13      0.12    0.17      0.01    0.15    Non-kinase Cdc42 effector protein SPEC2                                                                   *LOC56990*
  Transcription/translation                                                                                                                                                                                                                      
   yf71g02                                 5232     R40420                     Hs.16313    0.90      0.13    2.30      0.15    2.55    Kruppel-like zinc-finger protein GLIS2                                                                    *GLIS2*
   c-26a02                                 451      F07446                     Hs.13993    1.64      0.38    3.39      0.73    2.07    TBP-like 1                                                                                                *TBPL1*
   c-05c07                                 4917     Z38284; Z41997             Hs.26973    1.21      0.20    2.45      0.52    2.02    Bromodomain adjacent to zinc-finger domain, 2B                                                            *BAZ2B*
   c-24a11                                 114423   F07382                     Hs.75678    1.38      0.23    0.66      0.16    0.47    FBJ murine osteosarcoma viral oncogene homolog B                                                          *FOSB*
   yg90e12                                 10904    R56427; R56428             Hs.239      1.28      0.23    0.59      0.03    0.46    Forkhead box M1                                                                                           *FOXM1*
   yf61e03                                 4401     R13803; R37662             Hs.182447   7.20      1.01    2.75      0.60    0.38    Heterogeneous nuclear ribonucleoprotein C (C1/C2)                                                         *HNRPC*
   yf64g02                                 993      R37803                     Hs.6151     4.87      0.77    1.87      0.46    0.38    Pumilio homolog 2 (*Drosophila*)                                                                          *PUM2*
   yg53f10                                 1678     R62465; R25720             Hs.520      1.41      0.20    ND        ND      0.35    Nuclear receptor subfamily 2, group C, member 2                                                           *NR2C2*
   yg47e10                                 1548     R21283; R45373             Hs.14520    1.55      0.26    0.53      0.13    0.34    Eukaryotic translation initiation factor 2C, 1                                                            *EIF2C1*
   yg36d06                                 1872     R24568; R44373             Hs.76177    10.91     1.23    3.67      0.10    0.34    Transcription factor CP2                                                                                  *TFCP2*
   yg60b12                                 303      R35123; R49511             Hs.2186     3.12      0.63    0.94      0.07    0.30    Eukaryotic translation elongation factor 1 gamma                                                          *EEF1G*
   yg27a08                                 4127     R43968                     Hs.278589   9.43      1.24    2.76      0.40    0.29    General transcription factor II, i, pseudogene 1                                                          *GTF2IP1*
  Cellular traffic or structure proteins                                                                                                                                                                                                         
   yg19f05                                 200119   R20424; R43544             Hs.169793   1.51      0.36    7.37      1.32    4.86    Ribosomal protein L32                                                                                     *RPL32*
   yc86h03                                 2760     F12918; T75229             Hs.182625   2.38      0.26    7.78      1.17    3.27    Vamp (vesicle-associated membrane protein)-associated protein B and C                                     *VAPB*
   yc87f04                                 5084     R38549; T75126             Hs.22826    1.83      0.11    5.59      0.64    3.06    Tropomodulin 3 (ubiquitous)                                                                               *TMOD3*
   yf98g01                                 8512     R18713                     Hs.75196    2.96      0.63    9.29      0.80    3.14    Ankyrin repeat-containing protein                                                                         *G9A*
   yh17e09                                 1304     R59488; R59489             Hs.30991    0.78      0.19    2.32      0.11    2.97    Ankyrin repeat domain 6                                                                                   *ANKRD6*
   yf76d11                                 424      R13426; R40938             Hs.119324   0.84      0.08    2.07      0.35    2.48    Kinesin-like 4                                                                                            *KNSL4*
   c-27f03                                 1382     F07488                     Hs.89497    2.32      0.31    5.60      0.64    2.42    Lamin B1                                                                                                  *LMNB1*
   yc96a12                                 11155    F13331; T77651             Hs.159613   4.50      0.32    10.84     2.13    2.41    Thyroid hormone receptor binding protein                                                                  *AIB3*
   yf57c11                                 1225     R12822; r20734             Hs.1501     0.94      0.22    2.25      0.22    2.39    Syndecan 2                                                                                                *SDC2*
   yl71a06                                 10804    H05894                     Hs.6682     1.33      0.11    2.94      0.20    2.21    Solute carrier family 7, cationic amino acid transporter, y+ system, member 11                            *SLC7A11*
   yc99f07                                 11082    T78361                     Hs.103042   2.21      0.07    0.98      0.19    0.44    Microtubule-associated protein 1B                                                                         *MAP1B*
   yf72e08                                 2558     R13080; R40510             Hs.7979     2.05      0.34    0.80      0.15    0.39    Likely ortholog of mouse synaptic vesicle glycoprotein 2a                                                 *SV2*
   yc87h12                                 2952     F10545; F12946             Hs.21611    5.68      0.59    1.93      0.17    0.34    Kinesin family member 3C                                                                                  *KIF3C*
   yg54d05                                 604      R25813; R46810             Hs.117977   1.62      0.33    0.50      0.11    0.31    Kinesin 2 (60-70 kD)                                                                                      *KNS2*
   yf91b02                                 1980     R16352; R42300             Hs.103042   3.50      0.41    1.01      0.24    0.29    Microtubule-associated protein 1B                                                                         *MAP1B*
   yf72a03                                 115963   R13048; R40479             Hs.187958   1.46      0.34    0.40      0.06    0.28    Solute carrier family 6, member 8, accessory proteins BAP31/BAP29                                         *SLC6A8, DXS1357E*
  Immunity/inflammatory response                                                                                                                                                                                                                 
   yg75d06                                 25621    R54423                     Hs.179661   1.88      0.18    8.01      1.02    4.26    FK506-binding protein 1A (12 kD)                                                                          *FKBP1A*
   yg65b03                                 2453     R35324                     Hs.9688     0.86      0.13    3.67      0.60    4.26    Leukocyte membrane antigen                                                                                *IRC1*
   yg57f05                                 190007   R34428                     Hs.181244   3.83      0.24    9.76      1.22    2.55    MHC class I gene family                                                                                   
   yf51e08                                 2563     R12005; R39844             Hs.75682    0.89      0.04    2.05      0.21    2.31    Autoantigen                                                                                               *RCD-8*
   c-2bh04                                 190137   F03851; F07604             Hs.284394   1.13      0.07    0.56      0.07    0.50    Complement component 3                                                                                    *C3*
   yf59h02                                 5580     R13549; R20669             Hs.82689    1.05      0.21    0.47      0.10    0.44    Tumor rejection antigen (gp96) 1                                                                          *TRA1*
   yc86g03                                 8628     F10456; F12856             Hs.302749   1.51      0.35    0.58      0.09    0.39    FK506-binding protein 9 (63 kD)                                                                           *FKBP9*
  Protein processing                                                                                                                                                                                                                             
   yf68a10                                 1071     R40190;                    Hs.75890    0.55      0.13    2.09      0.23    3.80    Site-1 protease (subtilisin-like, sterol-regulated, cleaves sterol regulatory element binding proteins)   *S1P*
   c-2na07                                 2001     F04230; F07978             Hs.102      1.01      0.16    0.46      0.10    0.45    Aminomethyltransferase (glycine cleavage system protein T)                                                *AMT*
   yc85d05                                 6301     F10498; F12892             Hs.170197   1.45      0.22    0.59      0.10    0.41    Glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2)                         *GOT2*
   c-2ge12                                 2793     Z40826; Z46090             Hs.183212   1.14      0.19    0.45      0.09    0.39    Isoprenylcysteine carboxyl methyltransferase                                                              *ICMT*
   yg52f04                                 202164   R21082; R46258             Hs.235887   1.55      0.31    0.54      0.08    0.34    HMT1 (hnRNP methyltransferase, *Saccharomyces cerevisiae*)-like 1                                         *HRMT1L1*
  Proteases                                                                                                                                                                                                                                      
   yf64f07                                 2813     R13707; R37801             Hs.171501   1.27      0.24    ND        ND      0.39    Ubiquitin specific protease 11                                                                            *USP11*
  Metabolism                                                                                                                                                                                                                                     
   yc97f08                                 1805     R39698; T78043             Hs.2838     2.73      0.24    9.35      0.86    3.42    Malic enzyme 3, NADP(+)-dependent, mitochondrial                                                          *ME3*
   yg97d06                                 3929     R59198; R59256             Hs.78989    0.68      0.07    1.99      0.18    2.94    Alcohol dehydrogenase 5 (class III), chi polypeptide                                                      *ADH5*
   c-2ca07                                 1549     F03858; F07608             Hs.180616   1.04      0.12    0.50      ND      0.48    CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 1                                   *CD36L1*
   yc95g06                                 3164     R39463; T77281             Hs.155247   1.01      0.20    0.31      0.05    0.30    Aldolase C, fructose-bisphosphate                                                                         *ALDOC*
  Miscellaneous                                                                                                                                                                                                                                  
   yg24g06                                 3097     R19249; R44514             Hs.22654    0.48      0.08    2.93      0.67    6.12    Sodium channel, voltage-gated, type I, alpha polypeptide                                                  *SCNIA*
   yc89d05                                 10816    F10796; F13191             Hs.12365    1.26      0.20    5.46      0.36    4.34    Synaptotagmin XIII                                                                                        *SYT13*
   c-28e05                                 4334     F07514                     Hs.6126     2.04      0.50    7.19      1.11    3.52    Mannosidase, beta A, lysosomal-like                                                                       *MANBAL*
   yg35g09                                 4463     R20330                     Hs.88764    3.30      0.19    9.88      2.40    2.99    Male-specific lethal-3 (*Drosophila*)-like 1                                                              *MSL3L1*
   yg36c01                                 292      R24560; R44360             Hs.6430     1.50      0.22    4.40      0.78    2.93    Protein with polyglutamine repeat; calcium (Ca^2+^) homeostasis endoplasmic reticulum protein             *ERPROT213-21*
   yc98a06                                 1475     R37847; T78111             Hs.301789   1.55      0.27    4.52      0.35    2.92    Capping protein (actin filament) muscle Z-line, alpha 1                                                   *CAPZA*
   yf54h02                                 924      R11969                     Hs.4865     1.41      0.17    3.05      0.18    2.17    Voltage-gated sodium channel beta-3 subunit (*scn3b* gene)                                                *HSA243396*
   yf91a04                                 434      R16348; R42296             Hs.12152    1.00      0.24    2.03      0.16    2.04    APMCF1 protein                                                                                            *APMCF1*
   c-1ia09                                 4199     Z39718; Z43661             Hs.8834     0.64      0.15    1.30      0.19    2.02    Ring finger protein 3                                                                                     *RNF3*
   yg83b04                                 4211     R53332; R53937             Hs.7022     1.19      0.28    0.59      0.09    0.50    Dedicator of cytokinesis 3                                                                                *DOCK3*
   yf57d02                                 4610     R12627; R20528             Hs.334688   1.51      0.25    0.75      0.13    0.50    Phytanoyl-CoA hydroxylase interacting protein                                                             *PHYHIP*
   yg36h06                                 3087     R24595; R44400             Hs.7122     1.08      0.13    ND        ND      0.46    Scrapie responsive protein 1                                                                              *SCRG1*
   yf99b05                                 2822     R18211; R42149             Hs.79284    1.07      0.21    0.48      0.07    0.45    Mesoderm specific transcript (mouse) homolog                                                              *MEST*
   c-24h06                                 92359    Z40467; Z44591             Hs.171545   1.02      0.20    0.45      0.11    0.44    HIV-1 Rev binding protein                                                                                 *HRB*
   yd05d01                                 2346     R38832; T80384             Hs.13493    1.06      0.24    0.44      0.06    0.42    Like mouse brain protein E46                                                                              *E46L*
   yf74e11                                 2106     R13277; R40723             Hs.334851   1.95      0.41    0.80      0.17    0.41    LIM and SH3 protein 1                                                                                     *LASP1*
   yd01e11                                 3181     T78746                     Hs.168640   1.17      0.27    0.47      0.10    0.40    Homolog of mouse Ank                                                                                      *ANK*
   yf48e09                                 414      R12292; R12804             Hs.21050    1.22      0.26    0.47      0.07    0.38    g20 protein                                                                                               *LOC51161*
   yg16d07                                 1087     R43459; R17969             Hs.87125    9.91      2.06    3.35      0.51    0.34    EH-domain containing 3                                                                                    *EHD3*
   yf57d07                                 12763    R12632; R20533             Hs.109706   1.78      0.23    0.58      0.09    0.33    Hematological and neurological expressed I                                                                *HN1*
   c-2Ia12                                 200991   F04056; F07796             Hs.74376    1.00      0.07    0.33      0.01    0.33    Olfactomedin related ER localized protein                                                                 *NOE1*
   yf61b05                                 1882     R13783; R37641             Hs.297743   2.04      0.16    0.63      0.12    0.31    Carbonic anhydrase X                                                                                      *CA10*
   yf61a10                                 3960     R39112; R13989             Hs.2288     12.49     1.82    3.38      0.84    0.27    Visinin-like 1                                                                                            *VSNL1*
   yg53b12                                 8924     R25707; R62451             Hs.169047   2.34      0.46    0.54      0.12    0.23    Chondroitin sulfate proteoglycan 3 (neurocan)                                                             *CSPG3*

Abbreviations and column headings are as in Table [1](#T1){ref-type="table"}.

###### 

Messenger RNA or protein sequences differentially expressed in ceramide-dependent apoptosis

  ---------------------- -------- -------------------------- -------------------- --------- ------- --------- ------- ------- -----------------------------------------------------------------
  Clone ID               GENX     GenBank accession number   Unigene              C. int.   C. SD   S. int.   S. SD   Ratio   Similarity
                                                                                                                              
  Upregulated clones                                                                                                          
   yg51f11               229      R21710                     Hs.64691             1.32      0.16    6.34      0.43    4.80    KIAA0483 protein
   yg30b04               5093     R44721                     Hs.12896             1.31      0.12    5.99      0.29    4.57    KIAA1034 protein
   yf53g09               13       R12046                     Hs.90424             1.56      0.10    7.09      0.67    4.55    *Homo sapiens* cDNA: FLJ23285 fis, clone HEP09071
   yc94b11               223      F13362; T77404             Hs.101375            1.40      0.15    6.38      1.10    4.55    cDNA DKFZp434H205 (from clone DKFZp434H205)
   yg37d06               2008     R19640                     Hs.264636            1.70      0.39    7.39      1.60    4.34    KIAA0781 protein
   yf75c06               425      R13300; R40783             Hs.26409             0.83      0.18    3.55      0.67    4.27    cDNA DKFZp547K204 (from clone DKFZp547K204)
   yf79e07               2479     R14269; R40562             Hs.19150             0.93      0.15    3.91      0.25    4.22    cDNA DKFZp564A2164 (from clone DKFZp564A2164)
   yf49e01               6657     R11708                     Hs.21710             1.64      0.20    6.61      1.00    4.04    Hypothetical protein DKFZp761G0313
   yg07h12               200578   R22668                     Hs.7734              1.00      0.09    3.71      0.56    3.70    *H. sapiens* cDNA: FLJ21380 fis, clone COL03329
   yg32e10               5469     R23681                     Hs.106825            1.38      0.15    5.09      0.55    3.68    Hypothetical protein FLJ20300
   yf90d07               6203     R15369; R42110             Hs.323396            1.28      0.20    4.66      0.41    3.63    Hypothetical protein RP1-317E23 (LOC56181)
   yg91g03               1624     R56083; R56195             Hs272814             0.83      0.15    2.89      0.30    3.48    Chromosome 20 open reading frame 67
   yg11e11               2086     R17284                     Hs.106210            4.25      0.56    14.04     2.67    3.30    Hypothetical protein FLJ10813
   ym11b06               6715     H11788                     Hs.125034            1.98      0.16    6.52      0.85    3.29    *H. sapiens* cDNA FLJ10733 fis, clone NT2RP3001392
   yf80c08               772      R14304; R40254             Hs.59236             1.21      0.25    3.94      0.63    3.24    Hypothetical protein DKFZp434L0718
   yg18e11               4391     R20224                     Hs.41185             3.49      0.86    11.27     1.23    3.23    cDNA DKFZp564O1262 (from clone DKFZp564O1262)
   yc90h10               1343     F13218; T75433             Hs.141003            1.32      0.24    4.19      1.05    3.18    *H. sapiens* cDNA: FLJ21691 fis, clone COL09555
   yg42a11               200671   R24764; R45496             Hs.288368            0.45      0.10    1.41      0.11    3.14    *H. sapiens* cDNA: FLJ21314 fis, clone COL02248
   yc85f03               255      F12760; T74722             Hs.318401            3.03      0.42    9.46      0.80    3.12    HSPC039 protein (LOC51124)
   yc86g12               32       F12859; T75226             Hs.180948            4.61      0.28    14.27     1.89    3.10    KIAA0729 protein
   c-2lb03               1917     Z45263                     Hs.155182            6.48      1.55    19.98     3.34    3.08    KIAA1036 protein
   yf94d09               2836     R16328; R41404             Hs.6343; HS.306400   3.16      0.48    9.58      0.97    3.03    KIAA1464 protein
   yf49g10               2696     R11887                     Hs.40094             4.42      0.68    13.38     1.70    3.03    Human DNA sequence from clone 167A19 on chromosome 1p32.1-33
   yg67h02               1136     R35733; R49366             Hs. 325825           3.76      0.34    11.27     0.80    3.00    *H. sapiens* cDNA: FLJ20848 fis, clone ADKA01732
   yc89d09               2388     F13194; T75317             Hs.22109             3.52      0.07    10.11     1.40    2.87    KIAA0945 protein
   yf72d11               4469     R13137; R40616             Hs.6311              2.38      0.54    6.80      0.92    2.86    *H. sapiens* cDNA: FLJ20859 fis, clone ADKA01617
   yg73c09               51540    R51740                     Hs.288959            1.31      0.18    3.70      0.65    2.83    *H. sapiens* cDNA: FLJ20920 fis, clone ADSE00877
   yf50h09               9583     R11919;                    Hs.11637             3.87      0.33    10.71     1.31    2.77    *H. sapiens* mRNA; cDNA DKFZp547J125 (from clone DKFZp547J125)
   c-2ba02               4345     Z41723; Z44845             Hs.15921             1.93      0.37    5.31      1.02    2.75    Hypothetical protein FLJ10759
   yg36f12               11000    R25011; R45019             Hs.118983            1.13      0.27    3.00      0.46    2.65    *H. sapiens* cDNA FLJ12150 fis, clone MAMMA1000422
   c-24b10               1689     Z44563                     Hs.154919            2.67      0.43    6.60      1.44    2.47    KIAA0625 protein
   yf76a11               1849     R13420; R40930             Hs.7822              1.12      0.09    2.73      0.33    2.43    cDNA DKFZp564C1216 (from clone DKFZp564C1216)
   yc91c07               162      F10758; F13156             Hs.140833            0.61      0.14    1.46      0.32    2.41    *H. sapiens* mRNA full length insert cDNA clone EUROIMAGE 29222
   yc94c08               4310     R38361; T77413             Hs.119004            0.53      0.05    1.25      0.22    2.36    KIAA0665 gene product
   yg57f04               3072     R34427; R48960             Hs.326416            0.90      0.16    1.98      0.35    2.20    cDNA DKFZp564H1916 (from clone DKFZp564H1916)
   yg15g12               5559     R18075; R42970             Hs.22370             0.66      0.14    1.45      0.21    2.19    cDNA DKFZp564O0122 (from clone DKFZp564O0122)
   yg97d02               1018     R59194; R59252             Hs.5324              0.64      0.07    1.32      0.16    2.06    Hypothetical protein (CL25022)
   yc95f04               3851     F13386; R39459             Hs.7888              0.58      0.07    1.16      0.25    2.02    *H. sapiens* clone 23736 mRNA sequence
  Downregulated clones                                                                                                        
   yg42e05               4312     R45416; R25077             Hs.169330            1.05      0.23    0.52      0.05    0.49    Neuronal protein (NP25)
   yg89f11               2081     R55970; R55969             Hs.16443             1.16      0.27    0.56      0.06    0.49    *H. sapiens* cDNA: FLJ21721 fis, clone COLF0381
   yg33e09               5446     R20455; R44158             Hs.333389            1.39      0.19    0.67      0.17    0.48    Hypothetical protein MGC13090
   c-2aa11               1485     Z40609; Z44824             Hs.13485             1.44      0.23    0.70      0.16    0.48    KIAA1918 protein
   yf65e06               5690     R13865; R37007             Hs.301685            1.03      0.21    ND        ND      0.48    KIAA0620 protein
   yl76d07               37588    H05960; H06010             Hs.92418; Hs.63510   3.95      0.73    1.85      0.18    0.47    KIAA0141
   c-2cg09               201091   F03885; F07635             Hs.288361            1.06      0.10    0.49      0.02    0.47    *H. sapiens* cDNA: FLJ22696 fis, clone HSI11696
   yg64h02               2829     R35543; R51112             Hs.12239             2.94      0.61    1.35      0.30    0.46    CGI-10 protein (LOC51004)
   yf49c08               23982    R11699; R17677             Hs.322844            1.29      0.32    0.58      0.12    0.45    Hypothetical protein DKFZp564A176
   yg33g08               636      R20203; R44989             Hs.7750              8.39      1.43    3.60      0.64    0.43    Novel human gene mapping to chromosome 1
   yf53d08               532      R11837; R36955             Hs.246885            1.07      0.05    0.44      0.08    0.42    Hypothetical protein FLJ20783
   yg65h10               10701    R35431; R49229             Hs.222746            1.04      0.25    0.42      0.09    0.40    KIAA1610 protein
   yg69e11               1257     R36317; R49249             Hs.216958            1.16      0.28    0.44      0.10    0.38    KIAA0194 protein
   yf79f12               5599     R14349; R40677             Hs.179946            2.55      0.37    0.86      0.20    0.34    KIAA1100 protein
   yf86c11               1909     R15181; R41632             Hs.286013            1.06      0.14    0.34      0.08    0.32    Short coiled-coil protein
   yf78c09               1664     R14217; R40635             Hs.351029            10.44     1.29    3.36      0.75    0.32    *H. sapiens* cDNA FLJ31803 fis, clone NT2RI2009101
   yf61c10               1067     R13997; R39120             Hs.5008; Hs.21515    1.11      0.09    0.35      0.08    0.32    CG-87 protein
   yd06g01               2455     R38891; T81283             Hs.165570            1.41      0.07    0.45      0.10    0.32    *H. sapiens* clone 25052 mRNA sequence
   yf64f10               111134   R36936                     Hs.80285             8.72      0.83    2.76      0.35    0.32    mRNA cDNA DKFZp586C1723 (from clone DKFZp586C1723)
   yc91e03               11140    F13018; T77597             Hs.337629            5.27      1.08    1.67      0.22    0.32    cDNA DKFZp434D115 (from clone DKFZp434D115)
   yf65b02               8918     R13839; R36985             Hs.227913            1.09      0.24    0.32      0.05    0.30    API5-like 1
   yf60a03               1485     R13618; R38474             Hs.13485             2.13      0.36    0.65      0.09    0.30    KIAA1918 protein
   yf56a05               5140     R12419                     Hs.7132              1.97      0.33    0.57      0.08    0.29    KIAA0574 protein
   yg78h08               884      R51917; R54309             Hs.6449              1.20      0.28    0.34      0.08    0.28    CGI-87 protein (LOC51112)
   yf69g12               713      R40161                     Hs.288776            1.21      0.23    0.29      0.04    0.24    *H. sapiens* cDNA: FLJ21304 fis, clone COL02111
   yf93b11               2192     R16295; R40219             Hs.108504            1.25      0.16    0.24      0.05    0.20    Hypothetical protein FLJ20113
   yf51g08               2572     R12017; R39856             Hs.20977             1.11      0.20    0.19      0.04    0.17    Human DNA sequence from clone RP5-881L22 on chromosome 20
   yg26c11               904      R19006; R44076             Hs.226396            3.13      0.50    0.35      0.08    0.11    Hypothetical protein FLJ11126
  ---------------------- -------- -------------------------- -------------------- --------- ------- --------- ------- ------- -----------------------------------------------------------------

Abbreviations and column headings are as in Table [1](#T1){ref-type="table"}.

###### 

Unknown genes differentially expressed in ceramide-dependent apoptosis

  Clone ID               GENX     GenBank accession number   Unigene                C. int.   C. SD   S. int.   S. SD   Ratio   Similarity
  ---------------------- -------- -------------------------- ---------------------- --------- ------- --------- ------- ------- --------------------------------------------------------------------------------------------
  Upregulated clones                                                                                                            
   yf66a04               17755    R18781                                            1.04      0.24    5.19      0.59    4.98    ESTs
   yf88d07               3024     R15141; R41563             Hs.12381               1.21      0.09    5.83      0.85    4.80    ESTs
   yc85h07               11132    F12902; T74741                                    1.38      0.16    5.75      0.53    4.16    ESTs
   yg38a10               2564     R19870; R45098             Hs.182503              1.32      0.23    5.46      0.63    4.15    ESTs
   c-25h01               1301     Z44625                     Hs.29672               4.51      0.68    18.31     3.99    4.06    ESTs
   yg53c11               5862     R25710; R62454                                    1.83      0.19    7.36      0.59    4.02    ESTs
   yg02a02               5691     R18381; R42444             Hs.240816              1.52      0.23    6.08      0.94    4.00    ESTs
   yh09g12               4411     R61781; R61782                                    1.20      0.30    4.55      0.24    3.78    ESTs
   yf80c09               943      R14362                                            2.24      0.32    8.34      0.16    3.73    ESTs
   yd02e05               761      R39357; T80134             Hs.306425; Hs.327350   1.20      0.19    4.47      0.73    3.72    ESTs
   yg17c05               5291     R18746; R43067             Hs.238956              1.09      0.11    3.79      0.39    3.48    ESTs
   c-2ef12               1659     F07687                                            3.08      0.02    10.53     2.42    3.42    ESTs
   yf58e03               1072     R12737; R39789             Hs.119714              3.06      0.60    10.30     0.39    3.36    ESTs
   yl69a01               160      H00104                     Hs.21417               3.24      0.54    10.72     1.23    3.31    ESTs
   yc93d09               438      T77119                     Hs.21417               2.08      0.45    6.77      1.60    3.25    ESTs
   c-28f03               1425     F07517; Z40576                                    2.49      0.35    7.77      0.52    3.12    ESTs
   yg60e11               2509     R35134                                            4.12      0.92    12.87     1.02    3.12    ESTs
   yl96g09               11047    H09060                                            2.97      0.51    9.23      1.00    3.11    ESTs
   yg02f03               2758     R18419                     HS.18585               3.51      0.62    10.83     1.03    3.09    ESTs
   yf94d10               11844    R16329; R41405             Hs.197143              2.73      0.46    8.41      1.14    3.08    ESTs
   yf63f02               201117   R13594                     Hs.155639              1.92      0.25    5.75      0.77    3.00    ESTs
   yf98b09               16058    R18177; R42241             Hs.106359              1.07      0.24    3.17      0.27    2.95    ESTs
   yf80c07               1885     R14303                     Hs.32565               0.76      0.04    2.18      0.33    2.85    ESTs
   yc92a01               11141    F13028; T76925                                    4.87      0.12    13.72     2.61    2.82    ESTs
   yf76a02               711      R13339                     Hs.7913                5.21      0.78    14.52     3.06    2.79    ESTs
   yf55h04               664      R12357                                            3.64      0.18    9.99      1.24    2.75    ESTs
   yc85h06               11131    F12901; T74740                                    5.20      0.54    14.15     2.43    2.72    ESTs
   yc88c03               10642    F12878; R38624             Hs.106313              1.50      0.30    4.04      0.70    2.70    ESTs
   yg39a10               10317    R19899; R45120             Hs.89388               4.91      0.67    12.91     2.40    2.63    ESTs
   yh15d09               6818     R61465                                            4.60      0.37    11.88     1.21    2.58    ESTs
   yg02g01               1987     R18425; R42486             Hs.4983                1.11      0.27    2.75      0.51    2.47    ESTs
   yg08h03               201114   R22721; R43427             Hs.244482              0.70      0.17    1.60      0.08    2.28    ESTs, moderately similar to alternatively spliced product using exon 13A (*H. sapiens*)
   yg33b02               4208     R20161; R44947             Hs.22905               0.91      0.19    2.05      0.17    2.26    ESTs
   yg44c04               3106     R25497; R45563             None                   1.11      0.27    2.60      0.50    2.33    ESTs
   yg46g12               5388     R20696; R45358             Hs.311444; Hs.6591     0.90      0.17    1.95      0.48    2.16    ESTs
   yg42a06               2573     R25050; R45389             Hs.23558               0.57      0.14    1.22      0.22    2.13    ESTs
   yf63f11               5521     R36919                     Hs.25205               0.99      0.14    2.11      0.19    2.13    ESTs
  Downregulated clones                                                                                                          
   c-2eg10               1662     F03955; F07692                                    1.04      0.19    0.51      0.08    0.49    ESTs
   c-29f04               201571   Z40598; Z44804             Hs.184780              1.06      0.15    0.52      0.11    0.49    ESTs
   c-2la08               1913     Z40977; Z45261             Hs.125266              1.03      0.22    ND        ND      0.49    ESTs
   c-2ch10               3050     F03889; F07637             Hs.27278               2.42      0.49    1.12      0.24    0.46    ESTs, weakly similar to chain A, cyclophilin A complexed with cyclosporin A (*H. sapiens*)
   yg83b05               20476    R53938; R53333                                    1.27      0.10    0.56      0.13    0.44    ESTs
   yg36f04               5214     R24580                     Hs.27104               2.18      0.53    0.95      0.17    0.43    ESTs
   yf60a12               3065     R38592; R13746                                    6.52      1.15    2.61      0.42    0.40    ESTs
   yc86e07               2935     F10326; F12716             Hs.227993              7.76      0.94    3.02      0.59    0.39    ESTs
   yc90f10               10752    F10679; F13085             Hs.12395               1.12      0.20    0.43      0.08    0.38    ESTs
   yc97e12               4395     T78036                     Hs.23213               1.11      0.20    0.41      0.05    0.37    ESTs
   yf50h10               477      R11920; R39108             Hs.6777                2.39      0.56    0.82      0.16    0.34    ESTs
   yf74a06               16024    R13206; R40294                                    1.32      0.28    0.45      0.10    0.34    ESTs
   yg96d11               3143     R59141; R59142                                    1.30      0.19    0.43      0.08    0.33    ESTs
   yf51a04               958      R11976; R39818             Hs.4241                1.25      0.23    0.40      0.09    0.32    ESTs
   yg51e05               5025     R46483; R21387             Hs.23187               6.26      0.92    1.98      0.19    0.32    ESTs
   yg02h09               2969     R17514; R42608             Hs.139270              10.09     0.93    3.19      0.46    0.32    ESTs
   yf66f03               978      R37086                     Hs.23210               1.72      0.18    ND        ND      0.29    ESTs
   yf67b06               115094   R18860                     Hs.203213              1.72      0.28    ND        ND      0.29    ESTs
   yl91f12               4185     H08130; H08131             Hs.19515               2.86      0.33    0.70      0.17    0.25    ESTs
   yg14a03               2782     R17432; R42778             Hs.22217               1.57      0.27    0.34      0.06    0.22    ESTs
   yf52e12               4147     R12228; R39947             Hs.7237                1.57      0.30    0.34      0.06    0.22    ESTs
   yf50g11               1829     R11917; R39107             Hs.352354; Hs.244624   2.37      0.24    0.48      0.10    0.20    ESTs
   yf84f08               2237     R14545; R41206             Hs.349648              1.06      0.17    0.19      0.03    0.18    ESTs, weakly similar to KIAA1157 protein (*H. sapiens*)

Abbreviations and column headings are as in Table [1](#T1){ref-type="table"}.
